Stockscreener 앱 받기
28.56
2.00%
-0.49
전일 마감가:
$29.05
열려 있는:
$28.67
하루 거래량:
426.32K
Relative Volume:
0.42
시가총액:
$2.13B
수익:
-
순이익/손실:
$-64.16M
주가수익비율:
-22.48
EPS:
-1.2702
순현금흐름:
$-69.06M
1주 성능:
+1.79%
1개월 성능:
+65.52%
6개월 성능:
-22.91%
1년 성능:
-21.51%
1일 변동 폭
$28.10
$28.76
1주일 범위
$26.00
$30.23
52주 변동 폭
$14.80
$40.47
Cg Oncology Inc Stock (CGON) Company Profile
명칭
Cg Oncology Inc
전화
(949) 419-6203
주소
400 SPECTRUM CENTER DRIVE, IRVINE
CGON을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CGON
Cg Oncology Inc
|
28.54 | 2.13B | 0 | -64.16M | -69.06M | -1.2702 |
|
VRTX
Vertex Pharmaceuticals Inc
|
503.38 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
608.52 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
653.78 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.32 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
255.09 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Cg Oncology Inc Stock (CGON) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-16 | 개시 | Scotiabank | Sector Perform |
| 2025-01-07 | 개시 | TD Cowen | Buy |
| 2024-10-24 | 개시 | UBS | Buy |
| 2024-09-23 | 개시 | RBC Capital Mkts | Outperform |
| 2024-08-28 | 개시 | ROTH MKM | Buy |
| 2024-06-28 | 개시 | BofA Securities | Buy |
| 2024-02-20 | 개시 | Cantor Fitzgerald | Overweight |
| 2024-02-20 | 개시 | Goldman | Neutral |
| 2024-02-20 | 개시 | Morgan Stanley | Overweight |
| 2024-02-14 | 개시 | H.C. Wainwright | Buy |
모두보기
Cg Oncology Inc 주식(CGON)의 최신 뉴스
CG Oncology Jumps 25% on Positive Trial Results - Orange County Business Journal
CG Oncology, Inc. (NASDAQ:CGON) Given Consensus Recommendation of “Buy” by Analysts - Defense World
CG Oncology, Inc. (NASDAQ:CGON) Shares Purchased by Invesco Ltd. - Defense World
CG Oncology initiated with an Overweight at JPMorgan - TipRanks
CGON Stock: JP Morgan Initiates Coverage with Overweight Rating - GuruFocus
JPMorgan Initiates Coverage on CG Oncology With Overweight Rating, $41 Price Target - marketscreener.com
CGON: JPMorgan Starts Coverage with Overweight Rating and $41 Ta - GuruFocus
CG Oncology (NASDAQ:CGON) Reaches New 1-Year Low After Insider Selling - Defense World
Why CG Oncology, Inc. (CGON) Surged on Monday - MSN
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release - Yahoo Finance
Cg Oncology Inc’s (CGON) Stock Is Harder To Predict Than You Think - Stocksregister
SUO-CTC and CG Oncology Announce the 2025 Award Recipients for the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
CG Oncology, Inc. (NASDAQ:CGON) Shares Bought by Wells Fargo & Company MN - Defense World
A look into Cg Oncology Inc (CGON)’s deeper side - Sete News
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Could Cg Oncology Inc (NASDAQ: CGON) Be The Biggest Winner? - Marketing Sentinel
Barclays PLC Acquires 10,737 Shares of CG Oncology, Inc. (NASDAQ:CGON) - Defense World
CG Oncology's Bladder Cancer Drug Impresses InvestorsHere's Why - AOL.com
Cg Oncology Inc [CGON] Stock sold by Insider POST LEONARD E for $28000.0 - knoxdaily.com
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains? - MSN
TD Cowen Sticks to Its Buy Rating for CG Oncology, Inc. (CGON) - The Globe and Mail
CG Oncology (NASDAQ:CGON) Given Overweight Rating at Cantor Fitzgerald - Defense World
CG Oncology’s (CGON) Buy Rating Reaffirmed at HC Wainwright - Defense World
CG Oncology shares jump on positive clinical trial data for cancer drug - Mugglehead Magazine
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results - TipRanks
J&J Looks To Overcome Drug-Delivery Limitations In Bladder Cancer With TAR-200 - insights.citeline.com
CG Oncology (CGON) Surges 25%: What Drove the Dramatic Stock Move? - Wealth Daily
Crude Oil Down 2%; Roper Technologies Increases 2025 Outlook - Benzinga
CG Oncology’s Blistering Rally: What You Need to Know - RagingBull
Cantor Fitzgerald maintains CG Oncology stock with $75 target - Investing.com Australia
CG Oncology Reports Durable Responses for Cretostimogene in Bladder Cancer Treatment; Shares Rise - marketscreener.com
Biohaven gets an up to $600M investment; Prilenia, Ferrer make a deal in Europe - Endpoints News
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug - inkl
This Small Biotech Rival To J&J Just Rocketed 44% - Investor's Business Daily
Cantor Fitzgerald maintains CG Oncology stock with $75 target By Investing.com - Investing.com India
Dow Jumps Over 150 Points; Domino's Pizza Posts Upbeat Earnings - Benzinga
Cg Oncology Inc (CGON) did well last session? - uspostnews.com
CG Oncology (CGON) Announces Phase 3 Trial Results Discussion - GuruFocus
Contrasting CG Oncology (CGON) & Its Rivals - Defense World
CGON Shows Promising Results in Bladder Cancer Study | CGON Stoc - GuruFocus
CGON: Insights on Phase 3 BOND-003 Trial Results for Bladder Can - GuruFocus
CG Oncology announces Phase 3 BOND-003 data presented at AUA meeting - TipRanks
CG Oncology Reports Promising 24-Month Efficacy and Safety Data for Cretostimogene Monotherapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
CG Oncology Announces Best-In-Disease Durability Data In Bond-003 Cohort C & Promising Early Signal In Cohort P For Cretostimogene Grenadenorepvec - TradingView
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting - The Globe and Mail
CG Oncology Bladder Cancer Drug Shows 42% Complete Response at 24 Months | CGON Stock News - Stock Titan
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Monday, April 28, 2025 - The Manila Times
CG Oncology's Breakthrough Phase 3 Bladder Cancer Treatment Data: What The AUA Plenary Will Reveal - Stock Titan
Daily Market Movement: Cg Oncology Inc (CGON) Sees a 0.34 Increase, Closing at 20.48 - DWinneX
Taking a Closer Look At Cg Oncology Inc (CGON) Following Its Recent Trade - knoxdaily.com
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates - ADVFN
Cg Oncology Inc (CGON) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.27%
0.30%
자본화:
|
볼륨(24시간):